Publications
Detailed Information
In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Keam, Bhumsuk | - |
dc.contributor.author | Kim, Soyeon | - |
dc.contributor.author | Ahn, Yong-Oon | - |
dc.contributor.author | Kim, Tae Min | - |
dc.contributor.author | Lee, Se-Hoon | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.date.accessioned | 2020-04-27T11:18:23Z | - |
dc.date.available | 2020-04-27T11:18:23Z | - |
dc.date.created | 2018-08-13 | - |
dc.date.issued | 2015-01 | - |
dc.identifier.citation | Anticancer Research, Vol.35 No.1, pp.175-182 | - |
dc.identifier.issn | 0250-7005 | - |
dc.identifier.other | 43124 | - |
dc.identifier.uri | https://hdl.handle.net/10371/165346 | - |
dc.description.abstract | Background/Aim: The purpose of the present study was to explore the antiproliferative effect of BYL719, a specific inhibitor for phosphatidylinositol 3-kinase (PI3K) p110 alpha, in human head and neck cancer cell lines, as a single agent or in combination with the irreversible EGFR tyrosine kinase inhibitor, dacomitinib. Materials and Methods: Six head and neck cancer cell lines consisting of two PIK3CA mutant cell lines, SNU-1076 and Detroit562, and four PIK3CA wild-type cell lines, SNU-1066, SNU-1041, FaDu and SCC25, were analyzed. Results: The PIK3CA-mutant cell lines were more sensitive to BYL719 than the PIK3CA wild-type cell lines. Following BYL719 treatment, all PIK3CA wild-type cell lines, except for the SNU-1066 cell line, exhibited higher IC50 values compared to the PIK3CA mutant cell lines. Administration of BYL719 induced-cell cycle G(0)/G(1) arrest and resulted in increased apoptosis in a dose-dependant manner. Furthermore, the administration of BYL719 reduced the level of p-mTOR, p-AKT and p-S6 expression indicating the down-regulation of downstream signaling. Conclusion: BYL719, a PI3K alpha selective blocker, could be a promising factor in the treatment of head and neck cancer either as a single agent or in combination with dacomitinib. | - |
dc.language | 영어 | - |
dc.publisher | International Institute of Anticancer Research | - |
dc.title | In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 김동완 | - |
dc.contributor.AlternativeAuthor | 허대석 | - |
dc.citation.journaltitle | Anticancer Research | - |
dc.identifier.wosid | 000347735300022 | - |
dc.identifier.scopusid | 2-s2.0-84920383114 | - |
dc.citation.endpage | 182 | - |
dc.citation.number | 1 | - |
dc.citation.startpage | 175 | - |
dc.citation.volume | 35 | - |
dc.identifier.sci | 000347735300022 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.contributor.affiliatedAuthor | Heo, Dae Seog | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | SQUAMOUS-CELL CARCINOMA | - |
dc.subject.keywordPlus | OROPHARYNGEAL CANCER | - |
dc.subject.keywordPlus | HUMAN-PAPILLOMAVIRUS | - |
dc.subject.keywordPlus | PIK3CA MUTATIONS | - |
dc.subject.keywordPlus | HIGH-FREQUENCY | - |
dc.subject.keywordPlus | PATHWAY | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordPlus | GENE | - |
dc.subject.keywordPlus | AMPLIFICATION | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordAuthor | Head and neck squamous cell carcinoma | - |
dc.subject.keywordAuthor | PIK3CA | - |
dc.subject.keywordAuthor | BYL719 | - |
dc.subject.keywordAuthor | dacomitinib | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.